Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financi...(25194 956 OPERATING EXPENSES: ...),Health

Date:11/9/2009

25,194 956 OPERATING EXPENSES: Cost of services -- 13 -- 27 Research and development: Non-cash compensation 388 334 950 (395) Other research and development 1,527 2,208 4,357 37,277 -------------------------------------------- Total research and development 1,915 2,542 5,307 3,882 -------------------------------------------- Selling, general and administrative: Non-cash compensation 250 1,662 1,648 5,146 Other selling, general and administrative 904 2,284 3,473 6,249 -------------------------------------------- Total selling, general and administrative 1,154 3,946 5,121 11,395 -------------------------------------------- TOTAL OPERATING EXPENSES 3,069 6,501 10,428 48,304 -------------------------------------------- OPERATING INCOME (LOSS) 431 (6,133) 14,766 (47,348) OTHER INCOME (EXPENSE): Interest and other income (expense), net 129 (622) 377 (1,551) -------------------------------------------- INCOME (LOSS) FROM CONTINUING OPERATIONS 560 (6,755) 15,143 (48,899) Loss from discontinued operations -- (86) -- (175) -------------------------------------------- NET INCOME (LOSS) $ 560 $(6,841) $15,143 $(49,074) ============================================ NET INCOME (LO
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
3. Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
4. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
5. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
6. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
7. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
8. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
9. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
10. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
11. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology